Atara Biotherapeutics, Inc. (ATRA)
USD 5.58
(-5.83%)
USD 5.58
(-5.83%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 264.73 Million USD | 5.99% |
| 2022 | 249.78 Million USD | 32.5% |
| 2021 | 188.51 Million USD | 49.87% |
| 2020 | 125.78 Million USD | 141.14% |
| 2019 | 52.16 Million USD | -1.55% |
| 2018 | 52.98 Million USD | 32.74% |
| 2017 | 39.91 Million USD | 292.17% |
| 2016 | 10.17 Million USD | 3.07% |
| 2015 | 9.87 Million USD | 235.88% |
| 2014 | 2.94 Million USD | -95.32% |
| 2013 | 62.84 Million USD | 683.9% |
| 2012 | 8.01 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 228.15 Million USD | -13.44% |
| 2024 Q1 | 263.57 Million USD | -0.44% |
| 2023 Q3 | 239.62 Million USD | 0.27% |
| 2023 Q4 | 264.73 Million USD | 10.48% |
| 2023 FY | 264.73 Million USD | 5.99% |
| 2023 Q1 | 237.12 Million USD | -5.07% |
| 2023 Q2 | 238.98 Million USD | 0.79% |
| 2022 FY | 249.78 Million USD | 32.5% |
| 2022 Q1 | 172.96 Million USD | -8.25% |
| 2022 Q4 | 249.78 Million USD | 37.85% |
| 2022 Q3 | 181.2 Million USD | 1.43% |
| 2022 Q2 | 178.64 Million USD | 3.28% |
| 2021 Q2 | 125.25 Million USD | -4.09% |
| 2021 Q3 | 139.78 Million USD | 11.6% |
| 2021 FY | 188.51 Million USD | 49.87% |
| 2021 Q4 | 188.51 Million USD | 34.86% |
| 2021 Q1 | 130.6 Million USD | 3.83% |
| 2020 Q3 | 51.59 Million USD | 9.81% |
| 2020 FY | 125.78 Million USD | 141.14% |
| 2020 Q2 | 46.98 Million USD | 0.56% |
| 2020 Q4 | 125.78 Million USD | 143.78% |
| 2020 Q1 | 46.72 Million USD | -10.42% |
| 2019 Q3 | 46.34 Million USD | 10.7% |
| 2019 Q4 | 52.16 Million USD | 12.55% |
| 2019 FY | 52.16 Million USD | -1.55% |
| 2019 Q1 | 40.79 Million USD | -23.01% |
| 2019 Q2 | 41.86 Million USD | 2.63% |
| 2018 Q4 | 52.98 Million USD | 32.83% |
| 2018 FY | 52.98 Million USD | 32.74% |
| 2018 Q3 | 39.88 Million USD | -0.8% |
| 2018 Q2 | 40.2 Million USD | 18.52% |
| 2018 Q1 | 33.92 Million USD | -15.01% |
| 2017 Q1 | 8.6 Million USD | -15.46% |
| 2017 Q4 | 39.91 Million USD | 68.16% |
| 2017 FY | 39.91 Million USD | 292.17% |
| 2017 Q3 | 23.73 Million USD | 3.16% |
| 2017 Q2 | 23.01 Million USD | 167.45% |
| 2016 Q4 | 10.17 Million USD | -28.4% |
| 2016 Q3 | 14.21 Million USD | 34.5% |
| 2016 Q2 | 10.56 Million USD | 15.58% |
| 2016 Q1 | 9.14 Million USD | -7.4% |
| 2016 FY | 10.17 Million USD | 3.07% |
| 2015 Q1 | 3.72 Million USD | 26.63% |
| 2015 FY | 9.87 Million USD | 235.88% |
| 2015 Q3 | 6.63 Million USD | -44.03% |
| 2015 Q2 | 11.84 Million USD | 218.21% |
| 2015 Q4 | 9.87 Million USD | 48.92% |
| 2014 Q1 | 77.57 Million USD | 23.43% |
| 2014 Q2 | 2.28 Million USD | -97.06% |
| 2014 FY | 2.94 Million USD | -95.32% |
| 2014 Q4 | 2.94 Million USD | -96.19% |
| 2014 Q3 | 77.14 Million USD | 3283.73% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | 62.84 Million USD | 683.9% |
| 2013 Q4 | 62.84 Million USD | 0.0% |
| 2012 FY | 8.01 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AbCellera Biologics Inc. | 335.77 Million USD | 21.157% |
| Alkermes plc | 933.53 Million USD | 71.642% |
| Agenus Inc. | 462.29 Million USD | 42.735% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 93.464% |
| Aptorum Group Limited | 5.25 Million USD | -4936.108% |
| Ardelyx, Inc. | 130.76 Million USD | -102.454% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 44.661% |
| Bicycle Therapeutics plc | 224.41 Million USD | -17.968% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | -103.314% |
| ChromaDex Corporation | 26.5 Million USD | -898.699% |
| Chimerix, Inc. | 19.74 Million USD | -1240.77% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -652.577% |
| Caribou Biosciences, Inc. | 72.56 Million USD | -264.815% |
| CRISPR Therapeutics AG | 346.76 Million USD | 23.656% |
| Precision BioSciences, Inc. | 140.92 Million USD | -87.862% |
| Dyadic International, Inc. | 2.34 Million USD | -11210.315% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -1527.836% |
| Fortress Biotech, Inc. | 165.93 Million USD | -59.538% |
| Lantern Pharma Inc. | 2.73 Million USD | -9562.983% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | -270.362% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -7402.285% |
| Incyte Corporation | 1.59 Billion USD | 83.374% |
| IO Biotech, Inc. | 17.55 Million USD | -1407.946% |
| Jaguar Health, Inc. | 45.86 Million USD | -477.192% |
| Novavax, Inc. | 2.57 Billion USD | 89.708% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -634.192% |
| Opthea Limited | 264.6 Million USD | -0.051% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | -102.541% |
| ContextLogic Inc. | 206 Million USD | -28.512% |
| MiMedx Group, Inc. | 96.33 Million USD | -174.821% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -451.279% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -7401.94% |
| NextCure, Inc. | 14.99 Million USD | -1665.253% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -6449.604% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -3864.879% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -466.411% |
| Vaxcyte, Inc. | 167.44 Million USD | -58.099% |
| PDS Biotechnology Corporation | 33.25 Million USD | -695.977% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | -12.551% |
| Pharming Group N.V. | 244.07 Million USD | -8.466% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -2120.559% |
| Avidity Biosciences, Inc. | 127.79 Million USD | -107.162% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -3906.717% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -3906.717% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -221.152% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -3885.172% |
| Acelyrin, Inc. | 86.35 Million USD | -206.573% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -20276.127% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -1741.122% |
| Summit Therapeutics Inc. | 125.25 Million USD | -111.353% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -2692.858% |
| Senti Biosciences, Inc. | 52.57 Million USD | -403.576% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | -284.918% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | -74.729% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -13434.509% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -19721.963% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | -16.71% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -2726.252% |
| Wave Life Sciences Ltd. | 227.44 Million USD | -16.395% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 46.465% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -2325.646% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -862.288% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -2087.043% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | 45.595% |
| Immix Biopharma, Inc. | 3.72 Million USD | -7013.123% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -600.135% |
| MEI Pharma, Inc. | 8.35 Million USD | -3068.582% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -812.407% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 23.835% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | -81.488% |
| Fortress Biotech, Inc. | 165.93 Million USD | -59.538% |
| Precigen, Inc. | 41.64 Million USD | -535.71% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -430.212% |
| AlloVir, Inc. | 45.01 Million USD | -488.104% |
| C4 Therapeutics, Inc. | 130.33 Million USD | -103.116% |
| Fate Therapeutics, Inc. | 137.8 Million USD | -92.115% |
| ImmuCell Corporation | 18.81 Million USD | -1307.04% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -837.912% |
| Onconetix, Inc. | 23.18 Million USD | -1042.04% |
| PureTech Health plc | 125.58 Million USD | -110.805% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -2857.933% |
| Elevation Oncology, Inc. | 34.28 Million USD | -672.227% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -10727.607% |
| Seer, Inc. | 39.36 Million USD | -572.514% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | -328.138% |
| Innoviva, Inc. | 568.55 Million USD | 53.437% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -872.29% |
| ESSA Pharma Inc. | 3.49 Million USD | -7474.524% |
| GlycoMimetics, Inc. | 6.9 Million USD | -3735.586% |
| GT Biopharma, Inc. | 6.63 Million USD | -3891.18% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | -0.13% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | 2.774% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | -215.063% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -2608.564% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -874.401% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -8106.87% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | -258.88% |
| Aptose Biosciences Inc. | 15.8 Million USD | -1574.616% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -2298.03% |
| Soligenix, Inc. | 7.27 Million USD | -3539.017% |
| Century Therapeutics, Inc. | 175.94 Million USD | -50.468% |
| Kura Oncology, Inc. | 51.66 Million USD | -412.437% |
| TScan Therapeutics, Inc. | 121.28 Million USD | -118.281% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -6305.396% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -3902.734% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | -4.805% |
| Autolus Therapeutics plc | 263.9 Million USD | -0.314% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -2425.615% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | -197.92% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -464.479% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | 24.974% |
| GRI Bio, Inc. | 2.69 Million USD | -9715.907% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -32600.087% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -751.484% |
| IGM Biosciences, Inc. | 220.17 Million USD | -20.237% |
| INmune Bio, Inc. | 18.86 Million USD | -1303.536% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -3.219% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -893.682% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -9638.612% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -7970.535% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | -352.887% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | -175.31% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 67.834% |
| Verastem, Inc. | 71.18 Million USD | -271.897% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -438.342% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -586.233% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -441.026% |
| Histogen Inc. | 5.69 Million USD | -4546.919% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -5936.453% |
| Surrozen, Inc. | 8.14 Million USD | -3150.276% |
| Organovo Holdings, Inc. | 2.74 Million USD | -9533.734% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -84248.654% |
| Ovid Therapeutics Inc. | 56.22 Million USD | -370.808% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -1503.289% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -418.042% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -31916.327% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | -108.905% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -2348.169% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | -75.45% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -10053.432% |
| Apollomics, Inc. | 14.15 Million USD | -1770.522% |
| Amarin Corporation plc | 279.58 Million USD | 5.312% |
| Mesoblast Limited | 188.79 Million USD | -40.221% |
| Turnstone Biologics Corp. | 14.14 Million USD | -1771.183% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | -46.434% |
| Synaptogenix, Inc. | 5.52 Million USD | -4687.711% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -3882.175% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | -55.628% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -2993.713% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -14964.075% |
| Exelixis, Inc. | 678.44 Million USD | 60.979% |
| Better Therapeutics, Inc. | 23.84 Million USD | -1010.372% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | -61.379% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | 55.447% |
| NLS Pharmaceutics AG | 10.68 Million USD | -2378.745% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -16205.272% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -580.081% |
| Gritstone bio, Inc. | 125.91 Million USD | -110.242% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -1703.863% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -5102.484% |
| Avid Bioservices, Inc. | 275.66 Million USD | 3.966% |
| Insmed Incorporated | 1.66 Billion USD | 84.069% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -3340.787% |
| MediWound Ltd. | 27.18 Million USD | -873.756% |
| OmniAb, Inc. | 87.4 Million USD | -202.9% |
| Alector, Inc. | 487.66 Million USD | 45.714% |
| Seres Therapeutics, Inc. | 403.45 Million USD | 34.383% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -1336.825% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -589.899% |
| Zai Lab Limited | 240.17 Million USD | -10.225% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 57.982% |
| Aura Biosciences, Inc. | 29.22 Million USD | -805.789% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | -178.443% |
| Immunic, Inc. | 25.36 Million USD | -943.579% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | -282.366% |
| Veracyte, Inc. | 93.71 Million USD | -182.477% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -10017.237% |
| FibroGen, Inc. | 585.72 Million USD | 54.802% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -1422.953% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -40436.63% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -4581.053% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 96.542% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -3129.263% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | -215.078% |
| TG Therapeutics, Inc. | 169.08 Million USD | -56.569% |
| Galecto, Inc. | 5.89 Million USD | -4390.078% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -3095.739% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 89.889% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -818.517% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -1997.575% |
| XBiotech Inc. | 8.39 Million USD | -3052.733% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -1703.863% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -397.809% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | 27.092% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -884.731% |
| Theravance Biopharma, Inc. | 169 Million USD | -56.644% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 78.222% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | 47.098% |
| Vaxxinity, Inc. | 30.94 Million USD | -755.529% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 72.778% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -4289.493% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 64.476% |
| NexImmune, Inc. | 5.08 Million USD | -5106.981% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -71181.442% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -8509.694% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 96.275% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -5036.466% |
| Scopus BioPharma Inc. | 7.45 Million USD | -3451.376% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -906.827% |
| Ainos, Inc. | 7.39 Million USD | -3480.295% |
| Pluri Inc. | 34.11 Million USD | -676.076% |
| Prothena Corporation plc | 135.01 Million USD | -96.075% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | -8.898% |
| Celularity Inc. | 102.92 Million USD | -157.202% |
| Rallybio Corporation | 9.43 Million USD | -2705.585% |
| Cue Biopharma, Inc. | 24.44 Million USD | -982.982% |
| MeiraGTx Holdings plc | 319.99 Million USD | 17.268% |
| Omeros Corporation | 403.25 Million USD | 34.35% |
| Humacyte, Inc. | 114.67 Million USD | -130.853% |
| Immunocore Holdings plc | 228.15 Million USD | -16.031% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -5330.462% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | -244.977% |
| Blueprint Medicines Corporation | 918.64 Million USD | 71.182% |
| CalciMedica, Inc. | 4.02 Million USD | -6472.368% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -1416.932% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | -71.746% |
| Scholar Rock Holding Corporation | 85.81 Million USD | -208.488% |
| Sana Biotechnology, Inc. | 277.79 Million USD | 4.701% |
| Pulmatrix, Inc. | 15.96 Million USD | -1558.429% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -1578.406% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -975.896% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -5.553% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -421.275% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 78.133% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -732.945% |
| Nutriband Inc. | 1.07 Million USD | -24437.06% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -2389.749% |
| Vor Biopharma Inc. | 59.1 Million USD | -347.914% |
| Roivant Sciences Ltd. | 773.95 Million USD | 65.794% |
| Evogene Ltd. | 17.99 Million USD | -1371.568% |
| ProKidney Corp. | 29.21 Million USD | -806.13% |
| Applied Therapeutics, Inc. | 71.97 Million USD | -267.795% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -37451.969% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 85.985% |
| CorMedix Inc. | 11.91 Million USD | -2121.392% |
| BioLineRx Ltd. | 50.7 Million USD | -422.139% |
| Tango Therapeutics, Inc. | 149.45 Million USD | -77.129% |
| Galectin Therapeutics Inc. | 88.44 Million USD | -199.335% |
| Atai Life Sciences N.V. | 49.16 Million USD | -438.495% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -749.809% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -1373.861% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | -112.407% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -4582.26% |
| MediciNova, Inc. | 3.89 Million USD | -6702.811% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -1348.301% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -17499.241% |
| GeoVax Labs, Inc. | 3.51 Million USD | -7421.135% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 33.36% |
| Biomea Fusion, Inc. | 30.69 Million USD | -762.61% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 90.273% |
| Mereo BioPharma Group plc | 15.96 Million USD | -1558.533% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -748.482% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | -351.12% |
| Absci Corporation | 58.3 Million USD | -354.06% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -1289.831% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -725.697% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | -258.768% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | -202.613% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -683.935% |
| Allakos Inc. | 74.79 Million USD | -253.957% |
| Imunon, Inc. | 8.53 Million USD | -3003.42% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -1076.548% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -130.581% |
| BioAtla, Inc. | 48.98 Million USD | -440.43% |
| NLS Pharmaceutics AG | 10.68 Million USD | -2378.745% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -9426.268% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | -102.701% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -1762.364% |
| XOMA Corporation | 145.58 Million USD | -81.848% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -686.381% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -285.019% |
| aTyr Pharma, Inc. | 31.59 Million USD | -737.849% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | -328.214% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -488.758% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -446.951% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -9124.216% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -3145.09% |
| Akari Therapeutics, Plc | 4.58 Million USD | -5675.196% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -1392.884% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 83.95% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -65443.391% |
| UroGen Pharma Ltd. | 243.52 Million USD | -8.71% |
| Sutro Biopharma, Inc. | 321.08 Million USD | 17.55% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -9486.436% |
| Orgenesis Inc. | 35.53 Million USD | -644.998% |
| Entera Bio Ltd. | 1.37 Million USD | -19097.607% |
| GH Research PLC | 6.7 Million USD | -3850.679% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -3793.162% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -1306.22% |
| Xencor, Inc. | 283.55 Million USD | 6.638% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -8766.839% |
| Replimune Group, Inc. | 113.21 Million USD | -133.836% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -6946.212% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | -155.708% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -65443.391% |
| Portage Biotech Inc. | 4.45 Million USD | -5849.101% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -17499.241% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -1048.525% |
| OncoCyte Corporation | 49.29 Million USD | -437.01% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -6299.504% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -33096.277% |
| Purple Biotech Ltd. | 10 Million USD | -2546.027% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -4475.441% |
| scPharmaceuticals Inc. | 57.26 Million USD | -362.33% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -2037.024% |
| HilleVax, Inc. | 78.9 Million USD | -235.494% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -5142.277% |
| Tharimmune, Inc. | 1.81 Million USD | -14485.581% |
| Genprex, Inc. | 3.25 Million USD | -8035.159% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -876.197% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -4956.054% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -128412.136% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -73735.302% |
| OKYO Pharma Limited | 7.42 Million USD | -3467.45% |
| Savara Inc. | 37.19 Million USD | -611.806% |
| Curis, Inc. | 57.61 Million USD | -359.514% |
| Daré Bioscience, Inc. | 26.32 Million USD | -905.456% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -575.348% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -18233.449% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -1171.603% |
| BeiGene, Ltd. | 2.23 Billion USD | 88.148% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -1143.483% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | -0.891% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -1144.406% |
| Erasca, Inc. | 78.61 Million USD | -236.766% |
| bluebird bio, Inc. | 424.62 Million USD | 37.654% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -40302.013% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 85.993% |
| DBV Technologies S.A. | 42.8 Million USD | -518.54% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -40302.013% |
| Moderna, Inc. | 4.57 Billion USD | 94.21% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -3684.632% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -15886.413% |
| Molecular Templates, Inc. | 31.17 Million USD | -749.299% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -1450.879% |
| Travere Therapeutics, Inc. | 588.1 Million USD | 54.985% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | -112.63% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -864.883% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -626.177% |
| Cogent Biosciences, Inc. | 55.63 Million USD | -375.843% |
| MacroGenics, Inc. | 154.2 Million USD | -71.675% |
| RenovoRx, Inc. | 4.46 Million USD | -5827.788% |
| Adicet Bio, Inc. | 37.12 Million USD | -613.187% |
| Prime Medicine, Inc. | 60.78 Million USD | -335.563% |
| Aditxt, Inc. | 28.53 Million USD | -827.867% |
| Adagene Inc. | 45.16 Million USD | -486.094% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -146404.447% |
| Quantum-Si incorporated | 26.63 Million USD | -894.086% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 62.049% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -8601.41% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | -130.282% |
| SciSparc Ltd. | 1.59 Million USD | -16497.806% |
| Vericel Corporation | 127.7 Million USD | -107.302% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -4657.233% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | -210.146% |
| Generation Bio Co. | 171.63 Million USD | -54.248% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -2192.078% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -532.868% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | -4.763% |
| Invivyd, Inc. | 51.71 Million USD | -411.931% |
| Relay Therapeutics, Inc. | 91.97 Million USD | -187.827% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -3969.559% |
| Spero Therapeutics, Inc. | 75.49 Million USD | -250.661% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -25828.991% |
| 2seventy bio, Inc. | 310.12 Million USD | 14.636% |
| ADMA Biologics, Inc. | 193.97 Million USD | -36.478% |
| Clene Inc. | 38.95 Million USD | -579.662% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -632.671% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | -3.019% |
| GeoVax Labs, Inc. | 3.51 Million USD | -7421.135% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | -39.142% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -2073.582% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | -33.487% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -2070.884% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -450.259% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -401.003% |
| Vir Biotechnology, Inc. | 369.85 Million USD | 28.422% |
| Evaxion Biotech A/S | 17.61 Million USD | -1402.684% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | -64.504% |
| Verve Therapeutics, Inc. | 153.18 Million USD | -72.819% |
| Trevena, Inc. | 48.26 Million USD | -448.537% |
| Surrozen, Inc. | 8.14 Million USD | -3150.276% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -1125.909% |
| Cingulate Inc. | 10.36 Million USD | -2455.144% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -9526.727% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -609.898% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -7281.389% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -1913.194% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | 16.54% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -965.375% |
| Clearmind Medicine Inc. | 3.61 Million USD | -7233.363% |
| Kronos Bio, Inc. | 54.2 Million USD | -388.432% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -462.751% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -1063.173% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -1218.993% |
| Statera Biopharma, Inc. | 22.67 Million USD | -1067.444% |
| ImmunityBio, Inc. | 1.09 Billion USD | 75.721% |
| Korro Bio, Inc. | 51.75 Million USD | -411.545% |
| Kineta, Inc. | 7.22 Million USD | -3565.674% |
| BioVie Inc. | 9.7 Million USD | -2628.628% |
| Codexis, Inc. | 49.94 Million USD | -430.042% |
| Celularity Inc. | 102.92 Million USD | -157.202% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | -175.058% |
| Celcuity Inc. | 51.45 Million USD | -414.547% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -76591.657% |
| Cibus, Inc. | 206.11 Million USD | -28.439% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -523.273% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -905.106% |
| IN8bio, Inc. | 8.77 Million USD | -2917.955% |
| Kodiak Sciences Inc. | 213.59 Million USD | -23.945% |
| Annexon, Inc. | 47.11 Million USD | -461.855% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | -195.658% |
| Assembly Biosciences, Inc. | 96.37 Million USD | -174.701% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -1833.925% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 89.831% |
| Eyenovia, Inc. | 19.78 Million USD | -1238.378% |
| Puma Biotechnology, Inc. | 177.08 Million USD | -49.495% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -3346.622% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -998.531% |
| Arcellx, Inc. | 339.75 Million USD | 22.08% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -2125.038% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | -7.817% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -2668.326% |
| Moolec Science SA | 13.94 Million USD | -1798.374% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -513.494% |
| Geron Corporation | 146.12 Million USD | -81.168% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -423.896% |
| Royalty Pharma plc | 6.29 Billion USD | 95.796% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -565.565% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -89821.741% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -10660.352% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | -39.956% |
| Humacyte, Inc. | 114.67 Million USD | -130.853% |
| Structure Therapeutics Inc. | 29.05 Million USD | -811.277% |
| 89bio, Inc. | 59.96 Million USD | -341.497% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -900.397% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -22035.033% |
| Genelux Corporation | 8.42 Million USD | -3044.121% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -3761.362% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | -94.203% |
| Notable Labs, Ltd. | 4.42 Million USD | -5880.009% |
| Liquidia Corporation | 73.13 Million USD | -261.966% |
| Mustang Bio, Inc. | 17.61 Million USD | -1402.554% |
| Immunovant, Inc. | 48.95 Million USD | -440.772% |
| Quantum-Si incorporated | 26.63 Million USD | -894.086% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -589.719% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -8431.582% |
| Vera Therapeutics, Inc. | 73.86 Million USD | -258.423% |
| Acasti Pharma Inc. | 11.55 Million USD | -2190.69% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -1070.993% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -9638.612% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -617.886% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -19325.216% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -4242.766% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -965.975% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -1041.887% |
| PepGen Inc. | 34.63 Million USD | -664.445% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -2079.965% |
| United Therapeutics Corporation | 1.18 Billion USD | 77.607% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -3690.593% |
| Solid Biosciences Inc. | 38.45 Million USD | -588.374% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -2993.713% |
| Immuneering Corporation | 12 Million USD | -2104.59% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -84248.654% |
| Silo Pharma, Inc. | 1.56 Million USD | -16769.946% |
| Belite Bio, Inc | 4.21 Million USD | -6186.749% |
| XOMA Corporation | 145.58 Million USD | -81.848% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -10803.418% |
| Bionomics Limited | 10.15 Million USD | -2505.988% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -1131.841% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -1055.392% |
| uniQure N.V. | 624.01 Million USD | 57.576% |
| Cassava Sciences, Inc. | 14.19 Million USD | -1764.988% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -146404.447% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | -55.558% |
| Forte Biosciences, Inc. | 3.66 Million USD | -7121.358% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -101493.35% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -3823.744% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -3346.622% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -1422.953% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -2405.062% |
| Altimmune, Inc. | 16.54 Million USD | -1500.478% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 57.142% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -1055.392% |
| Compugen Ltd. | 55.77 Million USD | -374.648% |
| Peak Bio, Inc. | 20.75 Million USD | -1175.625% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | -139.659% |
| Benitec Biopharma Inc. | 4.96 Million USD | -5235.248% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | -67.72% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | -252.163% |
| Zura Bio Limited | 21.29 Million USD | -1143.354% |
| PolyPid Ltd. | 17.46 Million USD | -1415.543% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | -135.531% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | -252.163% |
| Instil Bio, Inc. | 99.8 Million USD | -165.263% |
| argenx SE | 444.95 Million USD | 40.502% |
| Immunome, Inc. | 28.65 Million USD | -823.773% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -3075.423% |
| Verona Pharma plc | 58.84 Million USD | -349.916% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -1729.165% |
| Shattuck Labs, Inc. | 14.85 Million USD | -1681.647% |
| CervoMed Inc. | 2.59 Million USD | -10098.798% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -5331.576% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -1978.635% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -2412.909% |
| Moolec Science SA | 13.94 Million USD | -1798.374% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -11196.546% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | -376.182% |
| AnaptysBio, Inc. | 364.28 Million USD | 27.328% |
| Design Therapeutics, Inc. | 11.95 Million USD | -2114.244% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -1987.157% |
| NeurAxis, Inc. | 1.91 Million USD | -13740.623% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -580.063% |
| Lumos Pharma, Inc. | 13.33 Million USD | -1885.562% |
| Achilles Therapeutics plc | 19.08 Million USD | -1286.991% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -1729.165% |
| 180 Life Sciences Corp. | 5.38 Million USD | -4814.14% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -1022.33% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -1063.173% |
| Nutriband Inc. | 1.07 Million USD | -24437.06% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -765.204% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -1724.375% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | 34.026% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -715.247% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -1928.761% |
| Palisade Bio, Inc. | 2.73 Million USD | -9565.389% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -4939.692% |
| Beam Therapeutics Inc. | 478.38 Million USD | 44.661% |
| Neurogene Inc. | 36.54 Million USD | -624.329% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | 33.475% |
| AEON Biopharma, Inc. | 159.88 Million USD | -65.574% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -455.582% |
| Sesen Bio, Inc. | 30.98 Million USD | -754.425% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -919.741% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -3382.34% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -35.25% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | -37.842% |
| Athira Pharma, Inc. | 30.05 Million USD | -780.777% |
| Vaccinex, Inc. | 5.94 Million USD | -4355.318% |
| HCW Biologics Inc. | 15.05 Million USD | -1658.809% |
| XOMA Corporation | 145.58 Million USD | -81.848% |
| Nektar Therapeutics | 267.04 Million USD | 0.865% |
| Arvinas, Inc. | 644.6 Million USD | 58.93% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -1392.884% |
| Merus N.V. | 102.15 Million USD | -159.16% |
| Omega Therapeutics, Inc. | 146.35 Million USD | -80.892% |
| Quince Therapeutics, Inc. | 95.12 Million USD | -178.317% |
| Rezolute, Inc. | 11.73 Million USD | -2156.136% |
| Clene Inc. | 38.95 Million USD | -579.662% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -9197.495% |
| BeyondSpring Inc. | 48.26 Million USD | -448.458% |
| Synlogic, Inc. | 32.89 Million USD | -704.788% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -1711.64% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -16101.652% |
| Peak Bio, Inc. | 20.75 Million USD | -1175.625% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | -317.175% |
| Krystal Biotech, Inc. | 39.71 Million USD | -566.604% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | 29.712% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | -165.881% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -61078.436% |
| MannKind Corporation | 721.36 Million USD | 63.301% |
| Ikena Oncology, Inc. | 22.33 Million USD | -1085.292% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -12591.035% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | -158.051% |
| Gossamer Bio, Inc. | 249.14 Million USD | -6.257% |
| CohBar, Inc. | 1.03 Million USD | -25511.965% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -2376.705% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -1289.831% |
| Legend Biotech Corporation | 589.93 Million USD | 55.125% |
| Mural Oncology plc | 37.92 Million USD | -597.994% |
| Biora Therapeutics, Inc. | 132.63 Million USD | -99.595% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -11433.626% |
| Disc Medicine, Inc. | 22.87 Million USD | -1057.311% |
| Champions Oncology, Inc. | 28.03 Million USD | -844.302% |
| REGENXBIO Inc. | 262.22 Million USD | -0.956% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -7780.538% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -2012.135% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -1870.982% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -1148.456% |
| Vaxart, Inc. | 34.02 Million USD | -678.06% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -1198.404% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -827.857% |
| Cellectis S.A. | 249.57 Million USD | -6.074% |
| Longeveron Inc. | 5.33 Million USD | -4860.371% |
| Repare Therapeutics Inc. | 41.81 Million USD | -533.05% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 88.993% |
| Inozyme Pharma, Inc. | 60.36 Million USD | -338.535% |
| Revolution Medicines, Inc. | 262.39 Million USD | -0.891% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -12464.547% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -2969.035% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -2143.327% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -1785.174% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -12207.531% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 94.859% |
| Denali Therapeutics Inc. | 122.96 Million USD | -115.296% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -4657.233% |
| Veru Inc. | 32.81 Million USD | -706.806% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -3754.054% |
| Cingulate Inc. | 10.36 Million USD | -2455.144% |
| Passage Bio, Inc. | 39.26 Million USD | -574.278% |
| Context Therapeutics Inc. | 4.19 Million USD | -6215.673% |
| Exicure, Inc. | 8.54 Million USD | -2996.678% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -797.163% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -2424.652% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -1101.102% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | -62.428% |
| Nuvalent, Inc. | 31.82 Million USD | -731.898% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -4061.435% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | -320.068% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -1370.75% |
| OmniAb, Inc. | 87.4 Million USD | -202.9% |
| Anew Medical, Inc. | 8.24 Million USD | -3112.102% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -591.411% |
| Lipocine Inc. | 2.63 Million USD | -9959.739% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -907.67% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -558.348% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -893.682% |
| G1 Therapeutics, Inc. | 86.15 Million USD | -207.281% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -4801.592% |
| Sage Therapeutics, Inc. | 82.74 Million USD | -219.933% |
| Ocugen, Inc. | 23.98 Million USD | -1003.844% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -470.464% |
| Q32 Bio Inc. | 233.12 Million USD | -13.558% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -2820.086% |
| Alumis Inc. Common Stock | 53.5 Million USD | -394.813% |
| Equillium, Inc. | 27.95 Million USD | -846.936% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | -28.144% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -4605.007% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -4216.589% |
| Galera Therapeutics, Inc. | 157.32 Million USD | -68.272% |
| Evelo Biosciences, Inc. | 69.43 Million USD | -281.281% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -2554.198% |
| Dominari Holdings Inc. | 4.63 Million USD | -5611.65% |
| Edesa Biotech, Inc. | 1.84 Million USD | -14274.983% |
| vTv Therapeutics Inc. | 29.56 Million USD | -795.373% |
| Bio-Techne Corporation | 744.34 Million USD | 64.434% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -109.942% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | 23.144% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -552.458% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -814.235% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | -186.634% |
| Nkarta, Inc. | 105.6 Million USD | -150.696% |
| BioCardia, Inc. | 4.59 Million USD | -5667.647% |
| Iterum Therapeutics plc | 32.66 Million USD | -710.529% |